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Abstract
The biotechnology and pharmaceutical industries are facing significant challenges to their
existing business models because of expiring drug patents, declining risk tolerance of ven-
ture capitalists and other investors, and increasing complexity in translational medicine. In
response to these challenges, new alternative investment companies have emerged to bridge
the biopharma funding gap by purchasing economic interests in drug royalty streams. Such
purchases allow universities and biopharma companies to monetize their intellectual prop-
erty, creating greater financial flexibility for them while giving investors an opportunity to
participate in the life sciences industry at lower risk. Royalty Pharma is the largest of these
drug royalty investment companies, and in this case study, we profile its business model
and show how its unique financing structure greatly enhances the impact it has had on the
biopharma industry and biomedical innovation.
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1 Introduction
Although the pharmaceutical industry has historically been a leader in financial perfor-
mance, it is now facing serious challenges to its business model. With blockbuster-drug sales
slowing,1 the industry has seen losses in the equity markets coupled with decreasing drug
development productivity. From 2001 to 2007, the average annual return for the pharma-
ceutical industry fell to −0.7% from its 1985–2000 average of 20.3%. By 2008, the industry
had seen an erosion of roughly $850 billion in shareholder value, despite rising gross margins
(8). Furthermore, the “patent cliff,”—the expiration of patents to highly profitable drugs
of several major pharmaceutical companies—is expected to put $209 billion in annual drug
sales at risk between 2010 and 2014 (12). For example, in 2011, Pfizer lost patent protection
on Lipitor, its most profitable product which accounted for 27% of its total revenues in 2006
(13).
The main challenge of the patent cliff is the difficulty in replacing these expiring drugs—
it has been estimated that large manufacturers will only be able to replace each dollar of
expiring-patent revenue with 26 cents of new product revenue. Of the new drugs approved
in 2009—part of a five-year stretch where major regulatory bodies approved 50% fewer new
molecular entities than in the previous five-year period—only 17% are considered blockbuster
medicines (12). Meanwhile drug-development costs have ballooned from an estimated $802
million to $1.2 billion per drug from 2003 to 2009 (4, 1).
These factors have potentially devastating effects on the ability of the biotechnology and
pharmaceutical industries to “translate” scientific discoveries into useful therapeutics, which
directly impacts patient health and life-expectancy. In a 2005 study, Lichtenberg found
that 40% of the two-year increase in life expectancy from 1986 to 2000 can be attributed
to new drug innovation (10). With more than 60% of all worldwide deaths caused by heart
disease, stroke, cancer, chronic respiratory diseases, and diabetes according to the World
Health Organization, the need for medical innovation has never been greater. The combi-
nation of reduced R&D productivity, increased economic risks, capital outflows, and loss of
revenues due to loss of patent protection and generic competition have created an urgency
for innovative financing approaches that can support more productive drug development.
Recently, a new approach to commercializing biomedical research based on financial en-
gineering techniques such as portfolio theory and securitization has been proposed (6). In
contrast to existing business models such as venture capital, private equity, and public eq-
uity (via publicly traded pharma companies), this new alternative—called a “megafund”—
1A “blockbuster” in the pharmaceutical industry is a drug that generates more than $1 billion in annual
revenues.
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involves the use of securitized debt, i.e., bonds that pay a fixed rate of interest and where
repayment is secured by collateral in the form of various biomedical projects that are funded
by the proceeds of the bonds. Because the bond market is considerably larger than venture
capital and public equity markets, and because debt can be structured to have longer ma-
turities which are better suited to drug development, such financing vehicles offer several
advantages to traditional sources of funding in the biopharma industry. However, these new
vehicles require new business models, and in this article we provide a detailed examination
of one structure—the drug royalty investment company—that offers a “proof of concept” for
certain aspects of the megafund model.
In this case study, we profile the business model of Royalty Pharma, Inc., the largest
of a new breed of investment companies that acquires ownership interests in drug royalties.
Founded in 1996 by Pablo Legorreta, an investment banker who successfully established a
proof-of-concept for investing in drug royalty streams several years earlier, Royalty Pharma
now manages $10 billion in assets, consisting of 39 approved and marketed biopharma prod-
ucts and two products in clinical trials and/or under review with the United States Food and
Drug Administration (FDA) and/or the European Medicines Agency (EMA). By focusing
on approved drugs, drug royalty investment companies are able to accurately estimate the
current market value of the drugs’ future royalty streams, allowing them to invest responsibly
and achieve an attractive risk/reward profile for their investors. From the perspective of the
patent-holders—typically universities, hospitals, and biomedical research centers—selling a
portion of their future royalty streams is often a welcome prospect because it provides these
institutions with much-needed cash to fund new research initiatives, as well as a concrete
lower bound for the value of the intellectual property.
However, perhaps the most interesting aspect of Royalty Pharma is the fact that it
has made use of debt financing since 2003 and raised new debt totaling $4 billion. This is
significant because the traditional sources of financing for the biopharma industry are private
and public equity; debt financing is feasible only for large pharmaceutical companies with
relatively stable cashflows, which is precisely what a portfolio of royalties on approved drugs
provides.
Debt financing is particularly important for biomedical R&D for at least two reasons.
First, debt maturities can range from a few months to 100 years,2 allowing the issuer to
customize the pattern of obligations to match their cashflows. Given that the drug-approval
process can often take a decade or more from beginning to end, long-term debt financing
may provide greater flexibility than traditional models such as venture capital or public eq-
2For example, in May 2011 the Massachusetts Institute of Technology issued $750 million in 100-year
bonds at the historically low rate of 5.623%.
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uity. Of course, equity capital is often preferred to debt financing by entrepreneurs because
the former is more “permanent” than the latter. However, permanent capital requires re-
linquishing certain control rights and, in the case of public equity, subjects the company to
quarterly earnings targets, daily stock price fluctuations, and a degree of transparency and
public scrutiny that discourages high-risk but truly transformative translational medical re-
search. In this respect, equity financing can lead to greater “short-termism” than long-term
debt. However, because of the highly predictable nature of Royalty Pharma’s cashflows, the
company is able to issue debt with relatively short maturities.
The second reason debt financing is important is the fact that the pool of potential bond
investors is much larger. For example, in 2012 the total amount of bonds issued in the U.S.
was $1.3 trillion, compared to $253 billion of public equity issued, and $126 billion of capital
committed to private equity (of which only $20 billion was venture capital, and only $6.8 was
invested in medical/health/life sciences companies). However, while the pool of capital is
larger, the risk appetite of bond investors is considerably lower than that of equity investors.
Therefore, the ability to tap into this larger pool of capital is to be able to reduce the
risk of the underlying assets to the point where debt financing is feasible. Royalty Pharma
has accomplished this feat by focusing only on approved drugs and, most recently, Phase
III compounds. This raises the possibility that other methods of de-risking a portfolio of
assets—such as the megafund proposed by Fernandez et al. (6)—might also be possible. In
any case, Royalty Pharma provides compelling proof that new financial methods and models
can play a pivotal role in helping the biopharma industry address its pressing short-term
funding needs and longer-term productivity challenges.
2 Industry Background
The challenges facing the biopharma industry and the need for new business models to
finance drug discovery are motivated by the lengthy, expensive, and risky nature of the drug
discovery process.
Before entering the market, a drug must pass through many levels of research and then
clinical trials, incurring varying costs at each stage. The new drug development process
starts in the so-called “preclinical” phase, which includes the search for certain chemical
compounds with potential medicinal value, testing the properties of candidate compounds
such as chemical stability, toxicity, and efficacy and side-effects in animals such as mice.
Once a compound demonstrates sufficient promise in the preclinical phase, the next step
is to begin testing it with human subjects which consists of three successive phases. In Phase
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I, general qualities such as safe dosages and metabolic effects are evaluated in a small number
of volunteers. Subsequently, preliminary efficacy and safety data are obtained in patients
with the target disease or condition during Phase II trials. Phase III consists of large-scale
trials and is the final clinical phase before approval. Upon successful completion of Phase
III trials, the drug developer can then submit a new drug application (NDA) to the FDA
for review and marketing approval.
Typically, the majority of drug discovery and preclinical data collection occurs outside of
pharmaceutical companies in academic institutions, as evidenced by the fact that only 12%
of active preclinical assets currently reside in large pharmaceutical companies (11). Phase I
and Phase II human trials are then typically conducted at small and mid-cap biotech com-
panies with the drug then being passed on to the main marketers—large-cap pharmaceutical
and biotech companies. Each stage has infrastructure and expertise suited for its role in
the development cycle. Recent trends indicate increasing collaboration between various in-
stitutions in the drug development cycle. As the complexity of drugs continues to increase,
more alliances between academic institutions, biotechnology companies, and pharmaceutical
companies have been launched (16). Just as pharmaceutical companies have reached back
to academic institutions to aid in the innovation gap, biotech companies are starting to do
so as well (12, 9).
Moreover, every four-year period between 1995 and 2009 has seen a 30% increase in licens-
ing deals between biotech companies and large-cap pharmaceutical companies. From 1995
to 1999, there were 180 reported licensing deals between biotech and the top 20 pharmaceu-
tical companies; this number grew to 238 between 2000 and 2004, and to 306 between 2005
and 2009 (11). This is a reflection of both the increasing complexity of new pharmaceutical
products and the exponentially increasing costs of the successive phases of clinical trials.
Cost sharing is a fundamental driver of these licensing deals which, in turn, are facilitated
by intellectual property that is protected by patents.
Pharmaceutical products are granted patent protection for a period of 20 years from the
date of the patent application, which is particularly important for this industry since most
drugs, once developed, can be imitated easily (15). This protection is designed to promote
innovation by allowing manufacturers to achieve above-average returns for a limited period.
With the 1984 introduction of the Hatch-Waxman Act, which significantly lowered the barrier
for generic market entry, most manufacturers aim to realize a majority of their returns on
a given product before patent expiry. From 1984 to 2010, the overall generic market share
grew from 19% to 78% (2, 7). However, a significant risk to the returns on a product is
presented when generic competitors believe they can break a patent before expiry. This
risk, combined with the growing complexity of the science behind new medicines, presents
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the need to develop a strong patent before entering the market and motivates collaboration
between biotech and pharma.
Because it is simpler and less expensive for smaller biotech companies to conduct early
trials that do not require large infrastructure and large patient populations, big pharma has
relied on its smaller counterparts to conduct Phase I and Phase II trials. At the same time,
most small and mid-cap biotech companies have experienced difficulty in securing financing
in both equity and debt markets. To pay for the expenses of collaborations, therefore, such
companies have supplemented the traditional cash or work-for-hire payments by issuing
royalty-based licenses that do not immediately affect their bottom line. A royalty payment
is a percentage of sales or a fixed amount per unit sold that is derived from the use of a
proprietary asset. A royalty interest is a financial contract that allows an entity to collect a
future stream of royalty payments for a predetermined timeframe, typically in exchange for
an up-front cash payment. Upon patent expiration, the asset underlying the royalty is no
longer proprietary and the royalty payments cease.
Royalties play a significant role in the biopharmaceutical industry, where multiple licens-
ing agreements may be attached to a product as it passes through the various stages of the
drug-development cycle. Payments based on future earnings allow smaller companies to work
with more established firms and academia without affecting their already difficult financing
situation. Licensing royalties can be substantial to a manufacturer, with rates ranging from
10% to 30% of revenues (2).
The larger role of academic institutions in commercial drug development calls for a better
funding mechanism for rewarding academic contributions and a more efficient collaboration
between industry and academia. While this process is complicated by the fact that academic
and commercial interests are not always aligned, the evolving drug discovery model can be
useful in mitigating risks by sharing resources. Due to the high risk of early-stage R&D,
investors are reluctant to bear the full cost of this phase, which is often referred to as
the “Valley of Death,” because of the dearth of funding for such projects. Accordingly,
government funding bodies and charitable institutions play a larger role in this stage—at
the 20 most research-focused medical schools, an average of 80–85% of total research dollars
comes from federal research grants (3).
However, there are several significant public-private collaborations in funding academic
research. For instance, the Broad Institute in Cambridge, MA is a partnership between
the Massachusetts Institute of Technology, Harvard University and its hospitals, and the
Whitehead Institute for Biomedical Research, and has been funded by charitable donations,
the Novartis Diabetes Initiative, and the RNAi consortium (14). Such partnerships are still
early in their life cycle and will require continued effort to become an efficient method of
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bringing new medicines to market. The growing complexity of collaborations with academia
has significant implications for the royalties attached to a product by the time it reaches the
market.
3 Brief Company History
Royalty Pharma is a privately owned alternative investment company that focuses on the
acquisition of pharmaceutical royalty interests. With a portfolio valued above $10 billion,
it is the global leader in dedicated royalty investment entities. Royalty Pharma, though
founded in 1996, has been through two distinct stages before becoming the company it is
today. In the 1980s, certain members of Royalty Pharma’s management team and investment
committee established Research & Development Partnerships to fund clinical development
of pharmaceutical products via royalty interests. In 1993 and 1994, Royalty Pharma founder
Pablo Legorreta developed two acquisition vehicles to acquire royalty interests in Neupogen
and ReoPro, two leading biotechnology products. Prior to creating the investment vehicles,
Mr. Legorreta provided cross-border merger and acquisition and corporate finance advisory
services at Lazard Fre`res. In 1996, the predecessors of Royalty Pharma were founded and in
2003, the predecessors were consolidated to form Royalty Pharma as it currently operates.
Figure 1 contains a size comparison between Royalty Pharma and other leading drug royalty
investment companies.
4 Investment Process
Royalty Pharma invests in products after regulatory approval and, more recently, also in the
late stages of clinical trials. Its current portfolio consists of royalty interests in 39 approved
and marketed biopharmaceutical products, and in two products in clinical trials and/or
under review with the FDA and/or EMA. Furthermore, it focuses on drugs with block-
buster potential that are marketed by leading pharmaceutical and biotech companies. The
management team manages everything, such as research and due diligence, except the final
investment decision, which is subject to the approval of a separate investment committee.
Once the management team conducts its due diligence and decides to pursue a poten-
tial project, the executive board must present the project to the investment committee for
approval before continuing. No investment can be made without approval from the invest-
ment committee. The seven-person investment committee is comprised of representatives of
several major investor groups and two independent directors from a variety of backgrounds,
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Figure 1: Size comparison of Royalty Pharma and other drug royalty investment companies,
based on consolidated RPI and RPS financials for the period ending March 30, 2012; pro
forma inclusion of the BG12 royalty asset and the $650 million RPIFT Term Loan Debt
(May 2012). (1) Cash and royalty receivables.
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with the CEO, Pablo Legorreta, being the only member of both the investment committee
and management team. This unique feature of Royalty Pharma’s investment committee
provides a degree of objectivity and investor representation that has served the company
well over the years.
Royalty Pharma identifies investment opportunities through two main methods. First,
it proactively searches for holders of royalties such as academic institutions, research insti-
tutions, and smaller companies. Second, as the largest royalty investment company, Royalty
Pharma is often contacted by potential sellers of royalties with new opportunities. Af-
ter identifying a potential investment, Royalty Pharma conducts research to determine the
commercial viability of the product in question. The product must be evaluated in three
separate parts to provide an accurate sales estimate from which Royalty Pharma obtains
its potential revenue stream. The pharmaceutical is measured by its scientific merit, the
strength of its patent, and its expected market share.
To establish the scientific value of the product, Royalty Pharma brings in opinion leaders
and clinicians to provide their opinions. The patent status of the product is established
by engaging patent attorneys who can attest to the strength of the patents. Finally, the
commercial value research is conducted by the Royalty Pharma management team by inter-
viewing key opinion leaders, specialists, community practice doctors, and other prescribers,
and compiling the resulting data into sales projections. In addition, because the products
are typically blockbuster drugs from large-cap marketers, many investment banks provide
sales projections for upcoming years. This increases visibility for future market share and
provides more data to which the in-house projections can be compared.
Due to the illiquid nature of the market in which it invests, Royalty Pharma does not
apply standard portfolio optimization techniques. It does, however, diversify its portfolio
in terms of product, therapeutic class, and marketer, and this diversification is achieved
in several ways. With respect to therapeutic class, Royalty Pharma’s portfolio consists of
products for over 15 indications,3 and with respect to exposure to marketers, the portfolio
covers products from 25 different marketers.
In addition, Royalty Pharma is diversified in terms of the type of investment it makes,
some of which go well beyond the standard royalty investment. Depending on the seller’s
desired cash flows, Royalty Pharma can provide many types of royalty investments, such as
an accelerated royalty or a synthetic royalty. In an accelerated royalty investment, Royalty
Pharma provides the seller with the cash flow from a royalty over a shorter duration than the
3An “indication” is an approved use for a drug, e.g., Humira for rheumatoid arthritis and beta-blockers
for high blood pressure. Indications are listed on the label of a drug, which is regulated by a government
regulatory body such as the U.S. Food and Drug Administration.
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actual royalty in exchange for receiving the remainder of the royalty. For example, the seller
receives its 9% royalty in three years instead of 3% over the course of nine years. In some
cases, a synthetic royalty is created when Royalty Pharma provides capital to a company
in exchange for a royalty where there is no existing royalty in the product. For instance, in
the case of Sunesis Pharmaceuticals’s Vosaroxin, Royalty Pharma agreed to provide capital
to finance a Phase III clinical trial in exchange for various percentages of future net sales,
depending on the status of the trial (see below for a more detailed discussion of this deal). In
this case, Royalty Pharma created a royalty instead of purchasing one. In other cases, Royalty
Pharma purchases an existing royalty in a pharmaceutical product outright. Therefore, its
portfolio is diversified in terms of type of royalties and products owned.
This stratified diversification approach seems to have paid off—Royalty Pharma’s port-
folio has delivered attractive risk-adjusted absolute returns with a remarkable level of con-
sistency. With the addition of conservative leverage, the returns to equity holders have been
increased without duly increasing the risk. While the absolute returns are impressive, the
stability of the equity returns through a period of unprecedented equity-market volatility and
notably poor performance across other asset classes support Royalty Pharma’s approach to
asset selection and portfolio construction.
5 Sample Deals
Royalty Pharma works closely and collaboratively with academic institutions, research insti-
tutions, and pharmaceutical/biotechnology companies to acquire royalty interests. In 2005,
Royalty Pharma acquired the emtricitabine royalty from Emory University and three inven-
tors. The royalty was 40% owned by three inventors and 60% owned by the Emory University
Medical School. The royalty, which represented a significant portion of the respective par-
ties’ net worth, was not ideal for the holders because it exposed them to single-product risk,
illiquidity, and a long payout schedule (15 years). Royalty Pharma purchased the royalty
for $525 million, providing the holders with the capital and liquidity with which to diversify
their assets.
Similarly, in 2006, Royalty Pharma purchased Cambridge Antibody Technology’s (CaT)
passive royalty interest in Abbott’s Humira. This occurred as part of AstraZeneca’s $1.3
billion purchase of the remaining 81% of CaT it did not already own. Since the non-core
passive asset was not as useful as upfront capital for AstraZeneca, it sold the royalty interest
to Royalty Pharma for $700 million. This, along with $300 million of CaT cash, brought As-
traZeneca’s net acquisition cost down to $300 million. Since the purpose of the collaboration
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between CaT and AstraZeneca was to develop antibody products and add to AstraZeneca’s
pipeline, the sale of a passive royalty interest did not undercut the main objective of the
acquisition.
While these examples involve approved products, Royalty Pharma also acquires royalties
in drugs that have yet to be approved such as the $761 million acquisition in May 2012 of an
interest in BG-12, a tablet version of the multiple sclerosis drug dimethyl fumarate. Royalty
Pharma’s interest represents a portion of an earn-out payable to the former shareholders
of Fumapharm by Biogen Idec, which acquired Fumapharm in 2006. The acquisition gave
Biogen Idec Fumaderm, a therapeutic approved in Germany for moderate to severe plaque
psoriasis. Biogen Idec adapted the base ingredient in Fumaderm, fumaric acid, into BG-12.
In April 2012, Biogen Idec presented its second set of promising Phase III data, bringing the
total to two global, placebo-controlled studies involving more than 2,600 relapsing-remitting
multiple sclerosis (RRMS) patients, further supporting BG-12’s NDA. The studies showed
a 44% to 53% reduction in annualized relapse rate when compared to the placebo. Fur-
thermore, BG-12 has not been associated with any increased risk for serious adverse effect
compared to the placebo. In addition, BG-12 was expected to be the first safe and effective
oral RRMS therapy and there was over 15 years of psoriasis safety data from Fumaderm.4
Given the strong data for the efficacy and safety of BG-12 at the time of Royalty Pharma’s
acquisition, it was expected to become the standard of care for multiple sclerosis. Less
than one year after Royalty Pharma’s acquisition, this drug was approved by the FDA on
March 27, 2013 and is now marketed as Tecfidera, and will be approved in Europe shortly.
Biogen Idec’s stock price, which was $177.09 on March 26, 2013—the day before the FDA
approval—has grown to $275.32 as of December 13, 2013, a 55.5% return that amounts to
a remarkable $23.2 billion increase in Biogen Idec’s market capitalization since BG-12 was
approved.
Royalty Pharma’s purchase provided the former Fumapharm shareholders with $761 mil-
lion in exchange for a portion of the earn-out payable to the former Fumapharm shareholders
linked to sales of BG-12 and Fumaderm. The structure of Fumapharm’s royalty with Biogen
Idec requires payments when net sales equal $500 million, $1 billion, and every subsequent
$1 billion up to $20 billion. To evaluate the expected revenue from this investment, Royalty
Pharma interviewed 105 U.S. and European neurologists. As is the case with any invest-
ment, there were risks involved with BG-12, primarily due to the drug’s unapproved status
4The current standard of care involves a group of drugs called the ABCRs (Avonex, Betaseron, Copaxone,
Rebif), which require painful daily to weekly injections for a lower efficacy (30% reduction). The other group
of treatments includes two drugs called Tysabri and Gilenya, which provide a higher efficacy but have severe
potential adverse effects including cancer and death.
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at the time of acquisition. Although the clinical trial data was strong and there was an
abundance of safety data from Fumaderm, the limited data with respect to multiple sclerosis
did leave some room for doubt. Furthermore, BG-12 had not yet launched and Biogen Idec
could, therefore, have delayed market entry for commercial reasons, though this was unlikely.
Finally, the upside is capped when net sales reach $20 billion due to the terms of the royalty.
Despite these risks, BG-12 was a viable investment due to the highly promising nature of
the product itself, sales projections, and visibility in the context of potential competitors,
both in-market and currently in-trials.
Another example of pre-FDA-approval financing is Royalty Pharma’s “adaptive financ-
ing” for Sunesis Pharmaceuticals using a creative synthetic royalty structure. At that time,
Sunesis was evaluating its lead product candidate, Vosaroxin, in a Phase-III, randomized,
double-blind, placebo-controlled trial—the VALOR trial—among patients with first relapsed
or refractory acute myeloid leukemia (AML). Initially designed to have a 90% probability
of detecting a 40% difference in overall survival among 450 patients, this trial employed an
“adaptive” structure that would allow for changes in design or analyses based on the exam-
ination of data at an interim point in the trial. Using the Access Control Execution System
(ACES) developed by Cytel—the leader in the design and implementation of adaptive clini-
cal trials—the Vosaroxin interim analysis was to be conducted by an independent data safety
monitoring board (DSMB) once 50% of the events were reached, i.e., 187 deaths. This was
expected to occur at approximately 300 patients enrolled, and based on this interim analysis,
the DSMB would then decide whether to stop the study early, continue the study as planned
with 450 patients, or implement a one-time increase in sample size with an additional 225
patients. By designing the study this way, Sunesis could avoid conducting an unnecessarily
large trial in certain cases, potentially reducing the overall cost and risk of their study.
While Sunesis had sufficient capital to fund the original Phase-III design of 450 patients,
the company was seeking an additional $25 million to fund the potential expansion to 675
patients at the interim analysis. Given Royalty Pharma’s interest in AML, the positive role
the company thought Vosaroxin could play in treating the disease, and the possibility of
expanding Vosaroxin’s use into additional blood cancers and solid tumors, discussions with
Sunesis were initiated in the Fall of 2011. After conducting its due diligence, in March 2012,
Royalty Pharma conditionally agreed to pay Sunesis the $25 million to acquire a royalty
on the future net sales of Vosaroxin. However, under the terms of the agreement, Royalty
Pharma would only invest the $25 million if, following the interim analysis, the study was
stopped early for efficacy or if the sample-size increase was implemented. In return, Royalty
Pharma would get a 3.6% participation payment on future net sales of the drug if the study
was stopped early for efficacy, or a 6.75% participation payment on future net sales plus two
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warrants if the sample size was increased. Each warrant would entitle Royalty Pharma to
purchase 1,000,000 shares of Sunesis common stock at an exercise price of $3.48 and $4.64 per
share, respectively. If the DSMB decided that the trial should continue as planned, Royalty
Pharma would have the option of making the $25 million investment upon the un-blinding
of the study in exchange for a 3.6% participation payment on future net sales.
This adaptive trial design enabled Royalty Pharma to invest in Vosaroxin on terms that
were a win-win for both parties. Sunesis received committed funding, greatly reducing their
risk and allowing them to focus on preparing Vosaroxin’s regulatory filings and U.S. com-
mercial launch and to expand their development program. Accordingly, upon the announce-
ment of this agreement, Sunesis’s stock price rose 15% and reached a two-year high when
the DSMB recommended the sample-size increase in September 2012. Royalty Pharma was
able to significantly limit its exposure to the risk of a negative outcome of the clinical trial
and, at the same time, position itself to receive a sizable royalty in the event that Vosaroxin
is approved. In addition, through the warrant portion of their investment, they stood to
earn back a significant portion of their initial investment upon the positive completion of
the trial. This type of “adaptive financing” is a potentially transformative technique for
commercializing biomedical research.
6 Financing
Royalty Pharma finances its acquisitions by an even mixture of debt and equity: $4.2 billion
and $4.0 billion, respectively. Equity investors are provided liquidity events once every four
years, with the most recent event occurring in 2011. The liquidity event in 2003 effectively
marked the start of Royalty Pharma’s current structure. By maintaining Royalty Pharma
as one investment vehicle and recapitalizing for each liquidity event, the fund is able to gain
access to low-cost debt capital. The reduced cost of capital allows Royalty Pharma to pay
higher prices for royalties while providing attractive returns to investors. Possible liquidity
options for 2015 include continuing the process of leveraged recapitalization or taking Royalty
Pharma public.
Over time, Royalty Pharma’s investor base has grown more institutional. In some cases,
royalty sellers are given the opportunity to reinvest a portion of the cash received in the
sale of the royalty and acquire equity in Royalty Pharma’s diversified portfolio. This occurs
as a separate process from the royalty acquisition, since the acquisition is paid for in full
and the seller then chooses to reinvest at the portfolio’s current net asset value. However,
the reinvestment, despite operating as a separate process, decreases the effective net acqui-
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sition cost to Royalty Pharma while providing diversification benefits to the royalty seller.
Furthermore, the seller can also receive the upside benefits of Royalty Pharma’s diversified
portfolio, including the royalty it sold.
The debt is held primarily by banks and other institutions, and is split into two main
trusts: RPI Finance Trust (RPIFT), a trust that continues to invest, and RP Select Finance
Trust (RPSFT), a trust that no longer invests and thus distributes 100% of its cash flow
after debt service to its equity investors. RPIFT, has approximately $3.35 billion of debt
outstanding across three tranches: $850 million of LIBOR+2.75% notes maturing in Novem-
ber 2016, $1.9 billion of LIBOR+3.00% notes maturing in May 2018, and $600 million of
LIBOR+3.00% notes maturing in November 2018. Based on total debt to EBIDTA, RPIFT
operates with a leverage ratio of 3.5-to-1. RPSFT consists of a single tranche of $850 million
notes at LIBOR+2.25% maturing in November 2016; this trust had an initial leverage ratio
of 4.0-to-1.
By creating two distinct vehicles, Royalty Pharma broadened the types of investors that
could purchase its debt, i.e., commercial banks purchased the short-term amortizing debt
while institutional lenders and funds purchased the longer-dated “bullet” debt. Further-
more, Royalty Pharma debt has received investment grade ratings by the three major rating
agencies (Moody’s, S&P, and Fitch), with ratings of Baa2, BBB−, and BBB−, respectively.
The rating agencies affirmed a stable outlook given the strong diversified portfolio, healthy
cash flow, and reasonable leverage of the Royalty Pharma portfolio.
Except for the $600 million tranche of RPIFT, which was raised in 2012, the remaining
$3.6 billion was refinanced in 2011 as part of the required liquidity event. In this event,
Royalty Pharma’s overall portfolio was split into a 20% run-off portfolio with the remaining
80% operating as a continuing investment vehicle. Royalty Pharma then refinanced its
existing $2.75 billion in outstanding debt and borrowed the additional $850 million on its
passive portfolio to distribute cash to shareholders.
7 Challenges and Future Prospects
Royalty Pharma has clearly been successful in creating a new segment of the investment
management industry, a particularly important one given the recent decline in investment
capital in the biopharma industry. However, the challenges facing that industry also have
implications for Royalty Pharma’s business model. The patent cliff will necessarily reduce
royalty streams for all the affected drugs and the combination of reduced R&D productiv-
ity, increasing complexity and economic risks, changes in the regulatory approval process,
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and targeted therapies and personalized medicine may have the effect of increasing Royalty
Pharma’s cost of capital.
At the same time, the number of scientific breakthroughs in translational medical research
has been growing, thanks to a confluence of innovations in basic science, bioengineering,
and computational advances such as high-throughput screening of chemical compounds, in
silica drug discovery, and faster and cheaper gene-sequencing techniques. Therefore, new
investment opportunities have never seemed greater, particularly at the earlier stages of the
drug development process. However, as investors move into earlier-stage assets, the economic
risk becomes greater since less is known about these assets’ efficacy, toxicity, and side effects.
Therefore, from a purely financial perspective, a larger amount of capital is required for these
earlier stage investments to bring down the risk to a more investor-friendly level.
Furthermore, while Royalty Pharma’s revolving equity structure has been successful to
date, with demand outstripping supply at each liquidity event, the size of its business would
be better served by permanent and more liquid capital, i.e., public equity. However, under
current law, drug royalty investment companies would become subject to entity-level tax if
they went public, which would render their cost of capital uncompetitive with their private
competitors. Royalty Pharma has advocated a change in the tax law that would enable
it to go public without becoming subject to entity-level tax, as is the case for real estate
investment trusts (REITs) and other publicly-traded partnerships.
Even without this change, Royalty Pharma is likely to continue its growth in the near
term given its track record and the demand for its services from both investors and patent
holders. The emergence of intellectual property exchanges such as IPXI also bodes well
for Royalty Pharma’s business model by creating greater liquidity and transparency into
otherwise hard-to-value royalty streams. But perhaps the most promising indication of
Royalty Pharma’s future is the current low-yield environment facing fixed-income investors
and the opportunity to issue large amounts of long-term debt securitized by royalty streams.
8 The Megafund Business Model
The Royalty Pharma business model clearly demonstrates that the megafund concept of
using both debt and equity to finance biomedical innovation is not only feasible but prac-
tical and scalable. By focusing on approved and late-stage therapeutics which have less
risky financial returns, drug royalty investment companies can access a much larger pool
of investment capital than traditional biotech venture capitalists. These financing vehicles
allow universities and biomedical research organizations to monetize their intellectual prop-
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erty, freeing up much-needed financial resources to be plowed back into basic research and
translational medicine.
However, the focus on late-stage assets does little to address the Valley of Death of
funding for preclinical and early-stage assets. While it is true that, by definition, drug royalty
investment companies currently focus only on assets for which royalties are imminent, they
highlight a key issue with respect to financing drug discovery: as we move from later-stage
to earlier-stage assets, the risks become greater, the likelihood of success is correspondingly
lower, and more projects and funding are needed to yield the same level of diversification as
that of portfolios of later-stage assets.
In fact, as we move to the very earliest stages of the drug discovery process—basic scien-
tific research—the practical relevance is so speculative that for-profit private-sector funding
is virtually non-existent for such activities. This stage can only be supported by the gov-
ernment and not-for-profit organizations such as foundations, endowments, high net worth
individuals, and patient-advocacy groups. The leading example is, of course, the National
Institutes of Health (NIH). A recent innovation of the NIH is the Bridging Interventional
Development Gaps (BriDGs) program, a non-profit initiative of the NIH’s National Center
for Advancing Translational Sciences that provides support—including investigational new
drug (IND)-directed toxicology, pharmacokinetic studies, and manufacturing of clinical trial
supplies—for researchers seeking to take basic research into the clinic.5
This spectrum of drug-discovery risk has a corresponding spectrum of possible financing
methods and natural investors, depicted in Figure 2. As drug discovery progresses from early
to late stages, and as the risk decreases along the way, the available sources of financing
progresses from grants and donations, which carry no expectation of any economic return,
to private and public equity, for which the returns are highly volatile but with unlimited
upside, to debt, for which the returns have very little volatility but very little upside.
This financing spectrum implies that the megafund proposed by Fernandez et al. (6)
will likely require a hybrid capital structure if it is to invest across the full spectrum of
drug discovery: securitized debt can finance the later-stage assets and various forms of
convertible bonds, and equity will be needed to finance earlier-stage assets. However, the
specific components of this hybrid capital structure will be highly dependent on the statistical
properties of the projects in the portfolio. For example, if the early-stage projects consist
primarily of therapeutics for rare diseases, i.e., “orphan drugs,” it can be shown that even a
relatively modest number of them (as few as 10) and equally modest funding (between $250
to $500 million) can provide sufficient diversification to yield attractive risk/reward profiles
5For more information, see http://www.ncats.nih.gov/research/reengineering/bridgs/bridgs.html.
15
Characteristics
Natural 
Investors
Financing 
Method
Stages
of Drug
Discovery
§ Low cost per project; many 
projects; top/down selection; 
high failure rate
§ Non-profits, 
hedge funds, VCs
§ Grants, gifts, 
private equity
Preclinical
High Risk
Phase I
Phase II Medium Risk
§ High cost per project; few 
projects; low failure rate
§ Medium cost per project; 
medium # of projects; 
medium failure rate
Low Risk
§ Hedge funds, 
VCs, pharma
§ Pharma, retail 
and institutional 
investors
§ Private and 
public equity, 
high-yield debt
§ Public equity, 
investment-grade 
debt
Phase III
NDA
Figure 2: Relationship between the stages of drug discovery, their financial characteristics,
the natural investors for each stage, and the type of financing method most appropriate.
Earlier-stage assets are more risky hence their financing vehicles naturally reflect investors
with those risk preferences.
for both debt and equity holders (5).
These considerations underscore the many new possibilities for financing biomedical in-
novation, and the opportunity for the biopharma industry to reinvent itself in light of these
new financing structures.
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A Appendix
In this appendix, we provide more detailed information about Royalty Pharma. We present
some basic facts and figures for the organization in Appendix A.1, include the biographies
of senior management in Appendix A.2, and provide an example of a typical term sheet for
a royalty acquisition deal in Appendix A.3.
A.1 Royalty Pharma Facts and Figures
Founded: 1996
Ownership: Privately Held
Employees: 21
Investment Focus: Biopharmaceutical royalty interests
Assets: Royalty interests in thirty-seven approved and marketed products
and five products in clinical trials and/or under review with the
United States Food and Drug Administration (FDA) and/or the
European Medicines Agency (EMA).
Main Office: 110 East 59th Street 33rd Floor
New York, NY 10022
Contact Information: ir@royaltypharma.com
(212) 883–0200 (tel)
A.2 Biographies of Senior Management
Pablo Legorreta, Founder and Chief Executive Officer
Mr. Legorreta founded Royalty Pharma in 1996, after creating and managing two “proof
of principle” investment vehicles in 1993 and 1994 that invested in royalty interests in two
leading biotechnology products. Prior to founding these investment vehicles, Mr. Legorreta
spent ten years at Lazard Fre`res where he provided cross-border merger and acquisition
and corporate finance advisory services to U.S. and European corporations. Mr. Legorreta
currently serves as a Director of Giuliani SpA and is a founding member of Boston Children’s
Hospital Medical Research Council, as well as a member of the Board of Trustees of The
Allen-Stevenson School. He received a degree in industrial engineering from Universidad
Iberoamericana.
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Susannah Gray, Executive Vice President and Chief Financial Officer
Ms. Gray joined Royalty Pharma in January 2005 after a fourteen year career in investment
banking. Prior to joining Royalty Pharma, Ms. Gray was a managing director and the senior
analyst covering the healthcare sector for CIBC World Markets (now Oppenheimer & Co.).
Prior to that, Ms. Gray worked at Merrill Lynch and Chase Securities (a predecessor of
JP Morgan), working in various capacities within the healthcare, high yield, and structured
finance groups. Ms. Gray received a BA with honors from Wesleyan University and holds
an MBA degree from Columbia University.
Alexander Kwit, Executive Vice President
Mr. Kwit joined Royalty Pharma in 2001 after practicing law for five years. Prior to joining
Royalty Pharma, Mr. Kwit served as Vice President of Business Affairs and General Counsel
for a New York based digital media entertainment company. Prior to that, Mr. Kwit was
an Associate at Davis, Polk & Wardwell, where he specialized in mergers & acquisitions and
securities laws. Mr. Kwit received a BA from Duke University, where he was elected to Phi
Beta Kappa, and holds a JD degree from Columbia University Law School, where he was a
Harlan Fiske Stone Scholar. He has been a member of the New York State Bar Association
since 1997.
Jim Reddoch, PhD, Executive Vice President, Head of Research & Investments
Dr. Reddoch joined Royalty Pharma in July 2008 after twelve years on Wall Street as a
biotechnology analyst. Prior to joining Royalty Pharma, Dr. Reddoch was Managing Direc-
tor and Head of Healthcare Equity Research at Friedman Billings Ramsey. Prior to that, Mr.
Reddoch worked at Banc of America Securities and CIBC World Markets (now Oppenheimer
& Co.). Dr. Reddoch holds a BA from Furman University and a PhD in biochemistry and
molecular genetics from the University of Alabama at Birmingham. He was a postdoctoral
fellow at the Yale University School of Medicine.
George Lloyd, Executive Vice President, Investments
Mr. Lloyd joined Royalty Pharma in 2011 after practicing law for 25 years. Prior to joining
Royalty Pharma, Mr. Lloyd was a partner in Goodwin Procter LLP’s Private Equity Group.
Prior to that, Mr. Lloyd was a partner at Testa Hurwitz & Thibeault LLP and an associate
at Davis Polk & Wardwell LLP. Mr. Lloyd received an AB from Princeton University and a
JD degree from New York University Law School, where he was on the Law Review.
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Molly Chiaramonte, PhD, Vice President, Research & Investments
Dr. Chiaramonte joined Royalty Pharma in January 2008. Prior to joining Royalty Pharma,
Dr. Chiaramonte worked as a biotechnology equity research associate at Jefferies & Company.
Prior to that, she was a postdoctoral fellow in the Department of Biochemistry and Molecular
Genetics at the University of Colorado Health Sciences Center. Dr. Chiaramonte received
a BA in mathematics, summa cum laude, from Providence College; an MA in mathematics
from the University of Colorado; and a PhD in chemistry (Biochemistry Program) from the
University of Colorado.
Terrance Coyne, Vice President, Research & Investments
Mr. Coyne joined Royalty Pharma in 2010. Prior to joining Royalty Pharma, Mr. Coyne
worked as a senior biotechnology equity research analyst at JP Morgan. Prior to that, he
worked at Rodman & Renshaw and Wyeth Pharmaceuticals. Mr. Coyne received a BS in
business administration from La Salle University and an MBA from La Salle University.
James S. Rielly, Vice President, Finance
Mr. Rielly joined Royalty Pharma in 1999. Prior to joining Royalty Pharma, Mr. Rielly was
the Vice President of Finance, Treasurer and Secretary of Cadus Pharmaceutical Corpora-
tion, a publicly traded biotechnology company. Prior to that, Mr. Rielly was the Controller
and Treasurer for Baring Brothers & Company Ltd, an investment banking firm. Mr. Rielly
is a certified public accountant and holds a BSBA from Bucknell University.
Alexander von Perfall, Vice President, Investor Relations
Mr. von Perfall joined Royalty Pharma in 2009. Prior to joining Royalty Pharma, Mr. von
Perfall was the Co-Founder and Chief Network Officer of XTF, a start-up exchange traded
fund ratings agency. Prior to joining Royalty Pharma, Mr. von Perfall worked at Bertelsmann
AG’s BMG Entertainment division and the International Finance Corporation/World Bank
Group. Mr. von Perfall attended the Hochschule St. Gallen in Switzerland and holds a
BA in politics from the University of San Francisco and an MBA from the Stern School of
Business at New York University.
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A.3 Sample Term Sheet
Figure 3: Sample term sheet for Humira royalty acquisition opportunity.
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